In this Industry Update KMC Health Care analyse the March 2021 PBAC Meeting Outcomes, including the resultant new resubmission categories, and provide Cost Recovery and Health Products Portal development updates. A brief overview of the status of the "Inquiry into...
As 2020 draws to a close, it has been a year like no other, KMC Health Care would like to look ahead to 2021 and take time to consider what it will bring..... PUBLIC SUMMARY DOCUMENTS Transparency will be the theme of PSDs moving into 2021. We’ve seen glimpses of the...
In the recently released PBAC Outcomes from the March 2020 meeting, it was reported that Dinutuximab Beta (Qarziba®) was not considered by the PBAC, but instead was referred to MSAC for funding consideration under the National Health Reform Agreement. So, what is the...
With imminent changes to reporting of Public Summary Documents, including changes to the publicly available economic (cost-effectiveness) and total financial cost ranges for new drugs recommended for PBS listing by the Pharmaceutical Benefits Advisory Committee...